Amgen Inc (AMGN · NASDAQ)

AMGN · MARKET VIEW

Market view · as of Sep 7, 2026

Revenue (TTM)
$38.09B
+9.5% YoY
Gross margin
71.9%
EPS (latest q)
$6.29
vs $5.60 est · beat
52-wk position
96.2%
-1.6% vs 52w high · +7.0% 1mo

Price (last ~year)

Amgen Inc. (AMGN) maintains a market capitalization of $236.38 billion, with second-quarter 2026 revenue reaching $10.05 billion. The company has posted four consecutive earnings beats, contributing to a 64.9% year-over-year increase in earnings and a 30.2% rise in share price over the last three months. With a 23.0% profit margin and $3.49 billion in free cash flow for the quarter, the biopharmaceutical firm currently carries $57.30 billion in total debt.

Valuation

Market cap
$236.38B
P/E
27.17
PEG
2.139
P/B
20.54
P/S
6.21
EV/EBITDA
16.08
Beta
0.426
Analyst target
$389.69

Quality & returns

Gross margin
71.9%
Operating margin
35.5%
Profit margin
23.0%
ROE
91.5%
ROA
8.7%

Price movement

Last
$437.23
1-month
+7.0%
3-month
+30.2%
RSI (14)
63
vs SMA200
+23.4%
52-wk position
96.2% -1.6% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-06-30$10.05B$3.51B$2.38B$3.44B
2026-03-31$8.62B$2.67B$1.82B$3.86B
2025-12-31$9.90B$3.94B$1.33B$3.30B
2025-09-30$9.56B$2.53B$3.22B$5.91B

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots